Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation
JAMA · 02.04.2024 · 331 (13) · 1099
DOI: 10.1001/jama.2024.3026 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 02.04.2024. Verfasst von Dhanunjaya R Lakkireddy und 17 weiteren Autor:innen. Beteiligte Einrichtung: Kansas City Heart Rhythm Institute, Overland Park. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Organothiophosphorus Compounds, Pulmonary Veins. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Left atrial appendage elimination may improve catheter ablation outcomes for atrial fibrillation.
Objective
To assess the safety and effectiveness of percutaneous left atrial appendage ligation adjunctive to catheter pulmonary vein isolation for nonparoxysmal atrial fibrillation. Design, Setting, and Participants This multicenter, prospective, open-label, randomized clinical trial evaluated the safety and effectiveness of percutaneous left atrial appendage ligation adjunctive to planned pulmonary vein isolation for nonparoxysmal atrial fibrillation present for less than 3 years. Eligible patients were randomized in a 2:1 ratio to undergo left atrial appendage ligation and pulmonary vein isolation or pulmonary vein isolation alone. Use of a 2:1 randomization ratio was intended to provide more device experience and safety data. Patients were enrolled from October 2015 to December 2019 at 53 US sites, with the final follow-up visit on April 21, 2021.
Interventions
Left atrial appendage ligation plus pulmonary vein isolation compared with pulmonary vein isolation alone. Main Outcomes and Measures A bayesian adaptive analysis was used for primary end points. Primary effectiveness was freedom from documented atrial arrythmias of greater than 30 seconds duration 12 months after undergoing pulmonary vein isolation. Rhythm was assessed by Holter monitoring at 6 and 12 months after pulmonary vein isolation, symptomatic event monitoring, or any electrocardiographic tracing obtained through 12 months after pulmonary vein isolation. Primary safety was a composite of predefined serious adverse events compared with a prespecified 10% performance goal 30 days after the procedure. Left atrial appendage closure was evaluated through 12 months after pulmonary vein isolation.
Results
Overall, 404 patients were randomized to undergo left atrial appendage ligation plus pulmonary vein isolation and 206 were randomized to undergo pulmonary vein isolation alone. Primary effectiveness was 64.3% with left atrial appendage ligation and pulmonary vein isolation and 59.9% with pulmonary vein isolation only (difference, 4.3% [bayesian 95% credible interval, −4.2% to 13.2%]; posterior superiority probability, 0.835), which did not meet the statistical criterion to establish superiority (0.977). Primary safety was met, with a 30-day serious adverse event rate of 3.4% (bayesian 95% credible interval, 2.0% to 5.0%; posterior probability, 1.0) which was less than the prespecified threshold of 10%. At 12 months after pulmonary vein isolation, complete left atrial appendage closure (0 mm residual communication) was observed in 84% of patients and less than or equal to 5 mm residual communication was observed in 99% of patients. Conclusions and Relevance Percutaneous left atrial appendage ligation adjunctive to pulmonary vein isolation did not meet prespecified efficacy criteria for freedom from atrial arrhythmias at 12 months compared with pulmonary vein isolation alone for patients with nonparoxysmal atrial fibrillation, but met prespecified safety criteria and demonstrated high rates of closure at 12 months. Trial Registration ClinicalTrials.gov Identifier: NCT02513797
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kansas City Heart Rhythm Institute, Overland Park.
- Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
- Valley Health System, Ridgewood, New Jersey.
- Texas Cardiac Arrhythmia Research, Austin.
- Vanderbilt University Heart-EP, Nashville, Tennessee.
- Baylor College of Medicine, Houston, Texas.
Zitieren
APA
Lakkireddy, D. R., Wilber, D. J., Mittal, S., Tschopp, D., Ellis, C. R., Rasekh, A., Hounshell, T., Evonich, R., Chandhok, S., Berger, R. D., Horton, R., Hoskins, M. H., Calkins, H., Yakubov, S. J., Simons, P., Saville, B. R., Lee, R. J., & aMAZE Investigators (2024). Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation. JAMA, 331(13), 1099. https://doi.org/10.1001/jama.2024.3026
Vancouver
Lakkireddy DR, Wilber DJ, Mittal S, Tschopp D, Ellis CR, Rasekh A, et al. Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation. JAMA. 2024;331(13):1099. doi:10.1001/jama.2024.3026
BibTeX
@article{Lakkireddy2024,
author = {Lakkireddy, Dhanunjaya R and Wilber, David J and Mittal, Suneet and Tschopp, David and Ellis, Christopher R and Rasekh, Abdi and Hounshell, Troy and Evonich, Rudy and Chandhok, Sheetal and Berger, Ronald D and Horton, Rodney and Hoskins, Michael H and Calkins, Hugh and Yakubov, Steven J and Simons, Pamela and Saville, Benjamin R and Lee, Randall J and aMAZE Investigators, aMAZE Investigators},
title = {Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation},
journal = {JAMA},
year = {2024},
volume = {331},
number = {13},
pages = {1099},
doi = {10.1001/jama.2024.3026}
}
EUVIMED